0001493152-21-009385.txt : 20210421
0001493152-21-009385.hdr.sgml : 20210421
20210421165329
ACCESSION NUMBER: 0001493152-21-009385
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210416
FILED AS OF DATE: 20210421
DATE AS OF CHANGE: 20210421
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chapman Christopher C JR
CENTRAL INDEX KEY: 0001340428
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36268
FILM NUMBER: 21842264
MAIL ADDRESS:
STREET 1: C/O STAR SCIENTIFIC, INC.
STREET 2: 7475 WISCONSIN AVENUE, SUITE 850
CITY: BETHESDA
STATE: MD
ZIP: 20814
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MyMD Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001321834
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 000000000
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1185 AVENUE OF THE AMERICAS
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 856-848-8698
MAIL ADDRESS:
STREET 1: 1185 AVENUE OF THE AMERICAS
STREET 2: 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Akers Biosciences, Inc.
DATE OF NAME CHANGE: 20170413
FORMER COMPANY:
FORMER CONFORMED NAME: Akers Biosciences Inc
DATE OF NAME CHANGE: 20050325
4
1
ownership.xml
X0306
4
2021-04-16
0
0001321834
MyMD Pharmaceuticals, Inc.
MYMD
0001340428
Chapman Christopher C JR
1185 AVENUE OF THE AMERICAS, 3RD FLOOR
NEW YORK,
NY
10036
1
1
0
0
President, Chief Med. Officer
Common Stock
2021-04-16
4
A
0
96475
A
96475
D
Stock Option (Right to Buy)
2.5913
2021-04-16
4
A
0
38590
A
2023-04-16
Common Stock
38590
38590
D
Stock Option (Right to Buy)
2.5913
2021-04-16
4
A
0
77180
A
2023-04-16
Common Stock
77180
77180
D
Stock Option (Right to Buy)
2.5913
2021-04-16
4
A
0
77180
A
2023-04-16
Common Stock
77180
77180
D
Stock Option (Right to Buy)
2.5913
2021-04-16
4
A
0
96475
A
2023-04-16
Common Stock
96475
96475
D
Received in exchange for 250,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share.
Received in the Merger in exchange for a stock option to acquire 100,000 shares of common stock of the Former Entity at $1.00 per share.
These options are fully vested and exercisable.
Received in the Merger in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share.
Received in the Merger in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share.
Received in the Merger in exchange for a stock option to acquire 250,000 shares of common stock of the Former Entity at $1.00 per share.
/s/ Chris Chapman
2021-04-21